MyoPax Receives Rare Pediatric Disease Designation from FDA for Breakthrough Regenerative Cell Product in Exstrophy-Epispadias Complex

BERLIN & COPENHAGEN, Denmark–(BUSINESS WIRE)–The U.S. Food and Drug Administration (FDA) granted a Rare Pediatric Disease Designation (RPDD) to MyoPax (, a young European biotech start-up developing innovative regenerative cell therapies for debilitating muscle disorders. The RPDD applies to a congenital muscle defect associated with Exstrophy-Epispadias Complex (EEC). This designation recognizes the potential of MyoPax’s patented technology to provide a novel therapeutic a

Recent Articles